In Vitro Susceptibility Data Provided Through the University of Pittsburgh Medical Center.
In Vitro Data Should Not Be Considered Representative of Clinical Efficacy¹

Established therapeutic utility in blepharitis, conjunctivitis, and other superficial ocular infections caused by Bacitracin-susceptible organisms

Excellent safety profile—low incidence of adverse events²

Ointment provides long-lasting ocular surface contact time and greater bioavailability³

Anti-infective efficacy in a lubricating base²

Flexible dosing—1 to 3 times daily²

Tier 1 pharmacy benefit status— on most insurance plans⁴

Indication

Bacitracin Ophthalmic Ointment is indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms.

Important Safety Information

This product should not be used in patients with a history of hypersensitivity to Bacitracin.
Bacitracin Ophthalmic Ointment should not be used in deep-seated ocular infections or in those that are likely to become systemic.
There is a low incidence of allergenicity exhibited by Bacitracin. If such reactions do occur, therapy should be discontinued.

Click here for full prescribing information.

NDC	Size	Case Pack
0574-4022-35	3.5 g	144 / 12

Bioequivalency Rating: RLD

References: 1. Antibiotic susceptibility: conjunctivitis and blepharitis. University of Pittsburgh Medical Center, Charles T. Campbell Eye Microbiology Lab Web site. http://eyemicrobiology.upmc.com/AntibioticSusceptibilities/Conjunctivitis.htm Accessed December 9, 2015. 2. Bacitracin Ophthalmic Ointment [package insert]. Minneapolis, MN: Perrigo Company; August 2013. 3. Hecht G. Ophthalmic preparations. In: Gennaro AR, ed. Remington: the Science and Practice of Pharmacy. 20th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2000. 4. Data on file. Perrigo Company.